News|Videos|January 27, 2023
Comparing BTK Inhibitors in the Treatment of Relapsed CLL
Drs Susan O’Brien and Catherine Coombs describe the design and outcomes of the ELEVATE-RR and ALPINE trials that compare BTK inhibitors in CLL.
Advertisement
Episodes in this series
Advertisement
Related to this article
!["Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.](https://cdn.sanity.io/images/0vv8moc6/cancernetwork/1cfb57db416943d8f8690afb0bc0d13aa3d90683-400x400.jpg?w=350&fit=crop&auto=format)
"Patients [with cancer] and physicians would rather have a fixed-duration treatment, if possible," said Julie M. Vose, MD, MBA, at SOHO 2026.
Amir T. Fathi, MD, explains which AML subgroups were excluded from PARADIGM and why chemotherapy remains standard for them.
Amir T. Fathi, MD, discusses how azacitidine/venetoclax’s lower toxicity and hospitalization burden should factor into treatment decisions.
Advertisement
Advertisement
Trending on CancerNetwork
1
Subcutaneous Pembrolizumab Approved in Japan for All Tumor Indications
2
Acting on a HER2 Result and Navigating Access to Therapy
3
The Case for Frontline Zongertinib in HER2-Mutant NSCLC
4
Emerging Endocrine Doublets and Serial ESR1 Testing in HR+/HER2− mBC
5